Case studies
Financial statements
At Syngene, our purpose goes beyond science. We are building a resilient, inclusive, and values-driven organization where people thrive and innovation flourishes. FY25 was a year of alignment between vision and action, with investments in wellbeing, equity, and sustainability reinforcing our commitment to long-term value creation for all stakeholders.
FY25 was a year marked by disciplined execution, strategic investments, and continued global expansion. In an increasingly complex and fast-moving scientific landscape, we remained agile, resilient, and purpose-driven in delivering value to all stakeholders. The global CRDMO industry is evolving rapidly as pharma and biotech companies seek integrated partners to accelerate innovation and improve efficiency. Syngene’s end-to-end capabilities ranging from discovery to commercial manufacturing, positions us at the heart of this transformation.
Our approach was shaped by a clear and compelling ambition to innovate for greater reach, explore new scientific paths, and deliver meaningful breakthroughs for our clients. This spirit was reflected in every aspect of our operations, from advancing research programs and enhancing development platforms, to scaling up manufacturing for global delivery.
India’s emergence as a key hub for pharmaceutical outsourcing is reshaping the global landscape. In FY25, Syngene joined ten other Indian CRDMOs to launch the Innovative Pharmaceutical Services Organization (IPSO)*, reinforcing our leadership and commitment to advancing the industry.
Amid global uncertainties, we remained focused on long-term value creation, expanding capabilities, entering new markets, and strengthening our technology platforms to meet the changing needs of our clients.
A key highlight of the year was our strategic acquisition of a biologics manufacturing facility in Baltimore, Maryland in the United States. This move significantly enhances our large molecule capabilities and strengthens our position in a high-growth industry area. Importantly, it gives us proximity to clients in North America and expands our ability to deliver end-to-end services across the biologics value chain.
We also sharpened our focus on differentiated technologies and scientific platforms aligned with the next-generation healthcare solutions. By investing in areas such as digital science and novel therapeutic modalities, we are positioning Syngene to support the future needs of the life sciences industry while unlocking new opportunities for collaboration.
Our people remain at the heart of everything we do. In FY25, we continued to invest in building a high-performing, inclusive, and values-driven organization.
As part of our commitment to building a purpose-driven workplace, we launched Thrive360 - a holistic wellbeing program designed to support our employees across physical, emotional, social, financial, and professional dimensions. Recognizing that employee wellbeing is fundamental to engagement and retention, we strengthened mental health support, expanded benefits, and introduced targeted initiatives such as complimentary cancer screenings, global Employee Assistance Program (EAP) coverage, and financial literacy programs. These efforts reflect our broader vision of fostering a resilient, inclusive, and future-ready workforce, one that thrives both within and beyond the workplace.
A strong culture of inclusion is essential to making Syngene a fair, high-performing, and reputable organization that attracts and retains top talent. We embrace diversity and ensure a workplace built on equity and respect. Our commitment to Diversity, Equity and Inclusion is reflected in our recognition as the #1 pharma company for women employees in Fortune India’s top 10 list, an achievement that underscores our dedication to fostering an inclusive and empowering workplace.
Our sustainability and governance practices continue to evolve, becoming more deeply integrated into Syngene’s operations and culture. In FY25, we made tangible progress across our Environmental, Social, and Governance (ESG) priorities, improving our performance and scores across multiple assessments including EcoVadis and Carbon Disclosure Project (CDP) reflecting our commitment to transparency and global best practices.
We have committed to Science Based Targets to reduce emissions by 54% by 2033 and strengthened our focus on sustainable innovation through memberships with the American Chemical Society’s (ACS) Green Chemistry Institute and the Pharmaceutical Supply Chain Initiative (PSCI).
At Syngene, we believe in driving lasting impact beyond our business through meaningful community initiatives. Our CSR efforts have empowered underserved communities through mobile science labs, preventive health interventions, mental wellbeing programs, and grassroots health infrastructure. Notable collaborations, such as the tribal health center in Devanalli (Uttara Kannada) and the Bengaluru Urban Mental Health Initiative (BUMHI) with NIMHANS, exemplify our commitment to inclusive development.
We also continue to support future talent through STEM scholarships, mentorship for women, and assistantships for underprivileged PhD students. Environmental stewardship remains a priority, with our investment in Bengaluru’s metro infrastructure promoting sustainable mobility. These efforts reflect our belief that science, compassion, and community engagement must go hand in hand to build a healthier, more equitable future for all.
FY25 has been a year of alignment between vision and execution, laying a strong foundation for the future. We move forward with confidence, committed to delivering sustainable value to all stakeholders.
Digital transformation and adoption of Artificial Intelligence (AI) are reshaping the CRDMO landscape by accelerating discovery, improving development precision, and enhancing manufacturing efficiency. These technologies are poised to play a pivotal role in shaping the next phase of growth for the CRDMO sector. At Syngene, we are integrating these tools across our value chain to drive smarter insights, streamline operations, and deliver faster, more impactful outcomes for our clients.
Opportunities in global life sciences are expanding, with clients seeking deeper, long-term partnerships. Syngene is well-positioned to meet this demand with a focused strategy, scaling operations, investing in innovation, and strengthening global relevance.
On behalf of the Board, I thank our shareholders, clients, partners, and employees for their continued trust and support.
*The association is currently under the registration process
